Please wait while the formulary information is being retrieved.
Drug overview for ALTACAINE (tetracaine hcl):
Generic name: TETRACAINE HCL
Drug class: Ophthalmic Local Anesthetics
Therapeutic class: Ophthalmic Agents
Tetracaine is an ester local anesthetic.
No enhanced Uses information available for this drug.
Generic name: TETRACAINE HCL
Drug class: Ophthalmic Local Anesthetics
Therapeutic class: Ophthalmic Agents
Tetracaine is an ester local anesthetic.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for ALTACAINE (tetracaine hcl) have been approved by the FDA:
Indications:
Administration of corneal anesthesia
Local anesthesia for ophthalmologic procedure
Professional Synonyms:
None.
Indications:
Administration of corneal anesthesia
Local anesthesia for ophthalmologic procedure
Professional Synonyms:
None.
The following dosing information is available for ALTACAINE (tetracaine hcl):
It isessential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
To produce local ophthalmic anesthesia, the usual dose is 1 drop topically in the eye(s) as needed.
To produce local ophthalmic anesthesia, the usual dose is 1 drop topically in the eye(s) as needed.
Apply topically to the eye in the form of a 0.5% solution. Not for injection or intraocular use; do not use intracamerally.
Administer under the direct supervision of a healthcare provider; not intended for patient self-administration. Open package using standard aseptic technique. The dispenser may then be allowed to fall upon a sterile surface.
The entire outer surface of the dispenser and its contents are sterile. Each dispenser is for single patient use and does not contain a preservative; discard any unused portion. Store at 2degreesC to 8degreesC; protect contents from light. Do not use if solution contains crystals, is cloudy, or discolored.
Administer under the direct supervision of a healthcare provider; not intended for patient self-administration. Open package using standard aseptic technique. The dispenser may then be allowed to fall upon a sterile surface.
The entire outer surface of the dispenser and its contents are sterile. Each dispenser is for single patient use and does not contain a preservative; discard any unused portion. Store at 2degreesC to 8degreesC; protect contents from light. Do not use if solution contains crystals, is cloudy, or discolored.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for ALTACAINE (tetracaine hcl):
There are 0 contraindications.
There are 1 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Long-acting Bupivacaine/Local Anesthetics SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Concurrent use of other local anesthetics or use of other local anesthetics within 96 hours following long-acting bupivacaine may result in additive neurologic and cardiovascular effects. Use of articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, and tetracaine may also increase the risk of methemoglobinemia.(1,2) Non-liposomal bupivacaine may impact the pharmacokinetic and/or physicochemical properties of the liposomal formulation when administered in the same syringe or used simultaneously unless the ratio of mg of non-liposomal bupivacaine to mg of bupivacaine liposomal does not exceed 1:2.(1) Local anesthetics other than bupivacaine may trigger the immediate release of bupivacaine from the liposomal formulation when administered together locally.(1) CLINICAL EFFECTS: Concurrent or use of local anesthetics with 96 hours of use of long-acting bupivacaine may result in neurologic and cardiovascular toxicity. Use of articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, and tetracaine may also result in methemoglobinemia.(1,2) Non-liposomal bupivacaine may impact the pharmacokinetic and/or physicochemical properties of the liposomal formulation when administered in the same syringe or used simultaneously unless the ratio of mg of non-liposomal bupivacaine to mg of bupivacaine liposomal does not exceed 1:2.(1) Local anesthetics other than bupivacaine may trigger the immediate release of bupivacaine from the liposomal formulation when administered together locally.(1) PREDISPOSING FACTORS: Use of additional agents that are associated with methemoglobinemia may further increase the risk of methemoglobinemia.(1) Patients who are at increased risk of developing methemoglobinemia include those with glucose-6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.(1) PATIENT MANAGEMENT: Avoid the use of other local anesthetics within 96 hours following the administration of long-acting bupivacaine. In patients for whom use is required, monitor for neurologic and cardiovascular effects. Also monitor for methemoglobinemia with use of articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, and tetracaine.(1,2) Non-liposomal bupivacaine may be administered in the same syringe as bupivacaine liposomal or injected immediately before bupivacaine liposomal as long as the ratio of mg of non-liposomal bupivacaine to mg of bupivacaine liposomal does not exceed 1:2.(1) Lidocaine may be administered 20 minutes or more prior to bupivacaine. It is unknown if other local anesthetics may be used without compromising the release characteristic of bupivacaine liposomal.(1) DISCUSSION: Concurrent use of other local anesthetics or use of other local anesthetics within 96 hours following long-acting bupivacaine may result in additive neurologic and cardiovascular effects. Use of articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, and tetracaine may also increase the risk of methemoglobinemia.(1,2) Non-liposome bupivacaine may impact the pharmacokinetic and/or physicochemical properties of the liposomal formulation when administered in the same syringe or used simultaneously unless the ratio of mg of non-liposomal bupivacaine to mg of bupivacaine liposomal does not exceed 1:2.(1) Local anesthetics other than bupivacaine may trigger the immediate release of bupivacaine from the liposomal formulation when administered together locally. Lidocaine may be administered 20 minutes or more prior to bupivacaine. It is unknown if other local anesthetics may be used without compromising the release characteristic of bupivacaine liposomal.(1) |
BUPIVACAINE LIPOSOME, EXPAREL, XARACOLL, ZYNRELEF |
There are 0 moderate interactions.
The following contraindication information is available for ALTACAINE (tetracaine hcl):
Drug contraindication overview.
None
None
There are 0 contraindications.
There are 0 severe contraindications.
There are 3 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Hyperthyroidism |
| Ocular infection |
| Ocular inflammation |
The following adverse reaction information is available for ALTACAINE (tetracaine hcl):
Adverse reaction overview.
Ocular adverse events: stinging, burning, conjunctival redness.
Ocular adverse events: stinging, burning, conjunctival redness.
There are 6 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
| None. | None. |
| Rare/Very Rare |
|---|
|
Cardiac arrhythmia Corneal opacity Excitement Fatigue Hyperhidrosis Pallor |
There are 7 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Conjunctival hyperemia Ocular irritation Ocular pain |
Ocular redness |
| Rare/Very Rare |
|---|
|
Allergic conjunctivitis Eyelid dermatitis Ocular itching |
The following precautions are available for ALTACAINE (tetracaine hcl):
Safety in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
There are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature.
There are no data to assess whether tetracaine hydrochloride ophthalmic solution is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for the drug and any potential adverse effects on the breastfed child from tetracaine or from the underlying maternal condition.
No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients.
The following prioritized warning is available for ALTACAINE (tetracaine hcl):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ALTACAINE (tetracaine hcl)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool